{"id":"NCT00770510","sponsor":"Eisai Co., Ltd.","briefTitle":"A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)","officialTitle":"A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-09","primaryCompletion":"2010-05","completion":"2010-05","firstPosted":"2008-10-10","resultsPosted":"2013-02-04","lastUpdate":"2013-02-04"},"enrollment":192,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Insomnia"],"interventions":[{"type":"DRUG","name":"Eszopiclone 1 mg","otherNames":["SEP-190"]},{"type":"DRUG","name":"Eszopiclone 2 mg","otherNames":["SEP-190"]},{"type":"DRUG","name":"Eszopiclone 3 mg","otherNames":["SEP-190"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Zolpidem Tartrate 10 mg","otherNames":[]}],"arms":[{"label":"Eszopiclone 1 mg","type":"EXPERIMENTAL"},{"label":"Eszopiclone 2 mg","type":"EXPERIMENTAL"},{"label":"Eszopiclone 3 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Zolpidem Tartrate 10 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to investigate and evaluate the efficacy of Eszopiclone in Japanese participants with primary insomnia.","primaryOutcome":{"measure":"Latency To Persistent Sleep (LPS)","timeFrame":"10 days (5 intervals of two consecutive nights)","effectByArm":[{"arm":"Placebo","deltaMin":37.5,"sd":37.8},{"arm":"Eszopiclone 1 mg","deltaMin":24.4,"sd":22.7},{"arm":"Eszopiclone 2 mg","deltaMin":20.9,"sd":24.3},{"arm":"Eszopiclone 3 mg","deltaMin":12.8,"sd":11.2},{"arm":"Zolpidem Tartrate 10 mg","deltaMin":14.3,"sd":22.6}],"pValues":[]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":20,"countries":["Japan"]},"refs":{"pmids":["23063301"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":71},"commonTop":["Dysgeusia","Somnolence","Dermatitis Contact","Dizziness","Feeling Abnormal"]}}